A Preliminary Study of Telemedicine for Patients with Hepatic Glycogen Storage Disease and Their Healthcare Providers: from Bedside to Home Site Monitoring

Overview

Journal J Inherit Metab Dis

Publisher Wiley

Date 2018 Mar 31

PMID 29600495

Citations 6

Authors

Irene J Hoogeveen

Fabian Peeks

Foekje de Boer

Charlotte M A Lubout

Tom J De Koning

Sebastiaan Te Boekhorst

Robert-Jan Zandvoort

Rob Burghard

Francjan J van Spronsen

Terry G J Derks

Affiliations

Soon will be listed here.

Abstract

Background: The purpose of this project was to develop a telemedicine platform that supports home site monitoring and integrates biochemical, physiological, and dietary parameters for individual patients with hepatic glycogen storage disease (GSD).

Methods And Results: The GSD communication platform (GCP) was designed with input from software developers, GSD patients, researchers, and healthcare providers. In phase 1, prototyping and software design of the GCP has occurred. The GCP was composed of a GSD App for patients and a GSD clinical dashboard for healthcare providers. In phase 2, the GCP was tested by retrospective patient data entry. The following software functionalities were included (a) dietary registration and prescription module, (b) emergency protocol module, and (c) data import functions for continuous glucose monitor devices and activity wearables. In phase 3, the GSD App was implemented in a pilot study of eight patients with GSD Ia (n = 3), GSD IIIa (n = 1), and GSD IX (n = 4). Usability was measured by the system usability scale (SUS). The mean SUS score was 64/100 [range: 38-93].

Conclusions: This report describes the design, development, and validation process of a telemedicine platform for patients with hepatic GSD. The GCP can facilitate home site monitoring and data exchange between patients with hepatic GSD and healthcare providers under varying circumstances. In the future, the GCP may support cross-border healthcare, second opinion processes and clinical trials, and could possibly also be adapted for other diseases for which a medical diet is the cornerstone.

Citing Articles

Development, Implementation, and Evaluation Methods for Dashboards in Health Care: Scoping Review.

Helminski D, Sussman J, Pfeiffer P, Kokaly A, Ranusch A, Renji A JMIR Med Inform. 2024; 12:e59828.

PMID: 39656991 PMC: 11651422. DOI: 10.2196/59828.

Quality assessment of mHealth apps: a scoping review.

Giebel G, Speckemeier C, Schrader N, Abels C, Plescher F, Hillerich V Front Health Serv. 2024; 4:1372871.

PMID: 38751854 PMC: 11094264. DOI: 10.3389/frhs.2024.1372871.

Towards values-based healthcare for inherited metabolic disorders: An overview of current practices for persons with liver glycogen storage disease and fatty acid oxidation disorders.

Venema A, Peeks F, Rossi A, Jager E, Derks T J Inherit Metab Dis. 2022; 45(6):1018-1027.

PMID: 36088581 PMC: 9828459. DOI: 10.1002/jimd.12555.

An update on the US adult thalassaemia population: a report from the CDC thalassaemia treatment centres.

Chapin J, Cohen A, Neufeld E, Vichinsky E, Giardina P, Boudreaux J Br J Haematol. 2021; 196(2):380-389.

PMID: 34775608 PMC: 10936238. DOI: 10.1111/bjh.17920.

A generic emergency protocol for patients with inborn errors of metabolism causing fasting intolerance: A retrospective, single-center study and the generation of www.emergencyprotocol.net.

Rossi A, Hoogeveen I, Lubout C, de Boer F, Fokkert-Wilts M, Rodenburg I J Inherit Metab Dis. 2021; 44(5):1124-1135.

PMID: 33844307 PMC: 8518720. DOI: 10.1002/jimd.12386.

References

Minarich L, Kirpich A, Fiske L, Weinstein D . Bone mineral density in glycogen storage disease type Ia and Ib. Genet Med. 2012; 14(8):737-741. PMC: 3884026. DOI: 10.1038/gim.2012.36. View

Hershkovitz E, Rachmel A, Phillip M . Continuous glucose monitoring in children with glycogen storage disease type I. J Inherit Metab Dis. 2002; 24(8):863-9. DOI: 10.1023/a:1013996325720. View

Dagli A, Zori R, McCune H, Ivsic T, Maisenbacher M, Weinstein D . Reversal of glycogen storage disease type IIIa-related cardiomyopathy with modification of diet. J Inherit Metab Dis. 2009; 32 Suppl 1:S103-6. PMC: 3808093. DOI: 10.1007/s10545-009-1088-x. View

Kasapkara C, Cinasal Demir G, Hasanoglu A, Tumer L . Continuous glucose monitoring in children with glycogen storage disease type I. Eur J Clin Nutr. 2013; 68(1):101-5. DOI: 10.1038/ejcn.2013.186. View

Valayannopoulos V, Bajolle F, Arnoux J, Dubois S, Sannier N, Baussan C . Successful treatment of severe cardiomyopathy in glycogen storage disease type III With D,L-3-hydroxybutyrate, ketogenic and high-protein diet. Pediatr Res. 2011; 70(6):638-41. DOI: 10.1203/PDR.0b013e318232154f. View

Ho G, Ueda K, Houben R, Joa J, Giezen A, Cheng B . Metabolic Diet App Suite for inborn errors of amino acid metabolism. Mol Genet Metab. 2016; 117(3):322-7. DOI: 10.1016/j.ymgme.2015.12.007. View

Sentner C, Hoogeveen I, Weinstein D, Santer R, Murphy E, McKiernan P . Glycogen storage disease type III: diagnosis, genotype, management, clinical course and outcome. J Inherit Metab Dis. 2016; 39(5):697-704. PMC: 4987401. DOI: 10.1007/s10545-016-9932-2. View

Kishnani P, Austin S, Arn P, Bali D, Boney A, Case L . Glycogen storage disease type III diagnosis and management guidelines. Genet Med. 2010; 12(7):446-63. DOI: 10.1097/GIM.0b013e3181e655b6. View

Tsilianidis L, Fiske L, Siegel S, Lumpkin C, Hoyt K, Wasserstein M . Aggressive therapy improves cirrhosis in glycogen storage disease type IX. Mol Genet Metab. 2013; 109(2):179-82. PMC: 3672367. DOI: 10.1016/j.ymgme.2013.03.009. View

10.

Rake J, Visser G, Labrune P, Leonard J, Ullrich K, Smit G . Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr. 2002; 161 Suppl 1:S20-34. DOI: 10.1007/s00431-002-0999-4. View

11.

Saliba V, Legido-Quigley H, Hallik R, Aaviksoo A, Car J, Mckee M . Telemedicine across borders: a systematic review of factors that hinder or support implementation. Int J Med Inform. 2012; 81(12):793-809. DOI: 10.1016/j.ijmedinf.2012.08.003. View

12.

Kostkova P, Brewer H, de Lusignan S, Fottrell E, Goldacre B, Hart G . Who Owns the Data? Open Data for Healthcare. Front Public Health. 2016; 4:7. PMC: 4756607. DOI: 10.3389/fpubh.2016.00007. View

13.

Melis D, Cozzolino M, Minopoli G, Balivo F, Parini R, Rigoldi M . Progression of renal damage in glycogen storage disease type I is associated to hyperlipidemia: a multicenter prospective Italian study. J Pediatr. 2015; 166(4):1079-82. DOI: 10.1016/j.jpeds.2014.12.015. View

14.

Visser G, Rake J, Labrune P, Leonard J, Moses S, Ullrich K . Consensus guidelines for management of glycogen storage disease type 1b - European Study on Glycogen Storage Disease Type 1. Eur J Pediatr. 2002; 161 Suppl 1:S120-3. DOI: 10.1007/s00431-002-1017-6. View

15.

Wolfsdorf J, Laffel L, CRIGLER Jr J . Metabolic control and renal dysfunction in type I glycogen storage disease. J Inherit Metab Dis. 1997; 20(4):559-68. DOI: 10.1023/a:1005346824368. View

16.

Tamborlane W, Beck R, Bode B, Buckingham B, Peter Chase H, Clemons R . Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008; 359(14):1464-76. DOI: 10.1056/NEJMoa0805017. View

17.

Raposo V . Telemedicine: The legal framework (or the lack of it) in Europe. GMS Health Technol Assess. 2016; 12:Doc03. PMC: 4987488. DOI: 10.3205/hta000126. View

18.

Maran A, Crepaldi C, Avogaro A, Catuogno S, Burlina A, Poscia A . Continuous glucose monitoring in conditions other than diabetes. Diabetes Metab Res Rev. 2004; 20 Suppl 2:S50-5. DOI: 10.1002/dmrr.518. View

19.

Wang D, Fiske L, Carreras C, Weinstein D . Natural history of hepatocellular adenoma formation in glycogen storage disease type I. J Pediatr. 2011; 159(3):442-6. PMC: 3135733. DOI: 10.1016/j.jpeds.2011.02.031. View

20.

Augustine E, Ray Dorsey E, Saltonstall P . The Care Continuum: An Evolving Model for Care and Research in Rare Diseases. Pediatrics. 2017; 140(3). DOI: 10.1542/peds.2017-0108. View